MEDICAL ADVOCATES
NEW AND NEWSWORTHY
 Drug/Vaccine Archives   

 Back to New and Noteworthy


 Files identified with this icon  are in Portable Document Format (PDF) and
require the Adobe Acrobat Reader


 
I    
Date Drug/Disease Citation  
 
Aug 24 Maraviroc Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients
With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2.
     
Aug 23 Raltegravir Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
     
Aug 21/22 Peginterferon Peginterferon Plus Ribavirin and Sustained Virological Response in HCV-Related
Cirrhosis: Outcomes and Factors Predicting Response.
     
Aug 29 Tenofovir Lower arterial stiffness and Framingham score after switching abacavir to tenofovir in men
at high cardiovascular risk.
     
Aug 19 Atazanavir
 Raltegravir		 Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation:
the minimal effect of raltegravir and atazanavir.
     
Aug 18 Tenofovir/
 Emtricitabine		 POSTER
 Switching from Kivexa [ABC/3TC ]+Kaletra [LPV/r] to Truvada [TDF/FTC]+Kaletra
[LPV/r] reduces high cholesterol: results of a 12 week randomized, controlled study \
PDF Poster     Abstract
     
Aug 17 Stavudine
Zidovudine		 Stavudine or zidovudine in three-drug combination therapy for initial treatment of
HIV infection in antiretroviral-naïve individuals.
     
Aug 16 Tenofovir Evolution of Drug Resistance During 48 Weeks of Zidovudine/Lamivudine/Tenofovir
in the Absence of Real-Time Viral Load Monitoring.
     
Aug 14/15 Nevirapine Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected
Cambodian patients (ANRS12154).
     
Aug 13 Darunavir The MONET trial 96 week analysis: darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs, for
patients with HIV RNA < 50 copies/mL at baseline
     
Aug 12 Tenofovir Systematic Review and Meta-analysis: Renal Safety of Tenofovir Disoproxil Fumarate in
HIV-Infected Patients.
     
Aug 11 Tenofovir/
Emtricitabine		 Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-
Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV.
 
     
Aug 10 Ritonavir Detrimental clinical interaction between ritonavir-boosted protease inhibitors
and vinblastine in HIV-infected patients with Hodgkin's lymphoma.
     
Aug 09 Raltegravir Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled
plasma viremia switching to a raltegravir-containing regimen.
     
Aug 07/08 Lopinavir Short Communication: Comparable Safety and Efficacy with Once-Daily Versus
Twice-Daily Dosing of Lopinavir/Ritonavir Tablets with Emtricitabine + Tenofovir DF
in Antiretroviral-Naïve, HIV Type 1-Infected Subjects: 96 Week Final Results of
the Randomized Trial M05-730.
     
Aug 06 Raltegravir Long-term successful control of super-multidrug-resistant human immunodeficiency
virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and
boosted-darunavir.
     
Aug 05 Peginterferon alfa-2a
 Peginterferon alfa-2b		 Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in
the daily routine treatment of patients with chronic hepatitis C in Germany:
The PRACTICE Study.
 
     
Aug 04 CMX157 Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection
caused by wild-type and nucleoside/nucleotide-resistant HIV.
     
Aug 03 Saquinavir Saquinavir/Ritonavir Monotherapy as a New Nucleoside-Sparing Maintenance
Strategy in Long-Term Virologically Suppressed HIV-Infected Patients.
     
Aug 02 Peginterferon alpha-2b FULL-TEXT PDF ARTICLE
Retreatment of hepatitis C patients with pegylated interferon combined with
ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
     
July 31/
Aug 01		 Ritonavir Combination of Suberoylanilide Hydroxamic Acid and Ritonavir is Effective Against
Renal Cancer Cells.
     
     


Back to New and Noteworthy

Home Page    
Drug Update Archives